SCHEMBL5044919

SCHEMBL5044919

CCOC(=O)C1=C(N)Oc2c(ccc3ccccc23)C1c1cc(Br)c(OC)c(OC)c1

nearest known ligand 0.63

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MYB P10242 14/20 0.63
MEN1 O00255 3/20 0.54
KMT2A Q03164 3/20 0.54
GAA P10253 1/20 0.54
TUBB4A P04350 2/20 0.46
TUBB P07437 2/20 0.46
TUBA3C P0DPH7 2/20 0.46
TUBA1B P68363 2/20 0.46
TUBA4A P68366 2/20 0.46
TUBB4B P68371 2/20 0.46
TUBB3 Q13509 2/20 0.46
TUBB2A Q13885 2/20 0.46
TUBB8 Q3ZCM7 2/20 0.46
TUBA3E Q6PEY2 2/20 0.46
TUBA1A Q71U36 2/20 0.46
TUBA1C Q9BQE3 2/20 0.46
TUBB6 Q9BUF5 2/20 0.46
TUBB2B Q9BVA1 2/20 0.46
TUBB1 Q9H4B7 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4541461 0.90 MYB (0.61) MYBMEN1KMT2AGAA
SCHEMBL20368810 0.90 MYB (0.55) MYBMEN1KMT2AGAATUBB4A
SCHEMBL4542953 0.85 MEN1 (0.52) MYBMEN1KMT2AGAATUBB4A
SCHEMBL4553376 0.84 TUBB4A (0.66) MYBMEN1KMT2AGAATUBB4A
SCHEMBL4538386 0.84 MYB (0.59) MYBTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL6014324 0.83 MYB (0.59) MYBTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL4538391 0.83 MYB (0.59) MYBTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL15370260 0.82 MYB (0.54) MYBMEN1KMT2ATUBB4ATUBB
SCHEMBL14523184 0.81 MYB (0.60) MYBMEN1KMT2AGAA
SCHEMBL4331540 0.79 MYB (0.87) MYBTUBB4ATUBBTUBA3CTUBA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2638025-B1 CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS DEUTSCHES KREBSFORSCHUNGSZENTRUM DKFZ (DE) 2020-02-05 EP disclosed
EP-2638026-B1 CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS DEUTSCHES KREBSFORSCHUNGSZENTRUM DKFZ (DE) 2018-07-11 EP disclosed
US-20160355496-A1 CHROMENE DERIVATIVES AND THEIR ANALOGS AS WNT PATHWAY ANTAGONISTS DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) 2016-12-08 US disclosed
US-20160355496-A1 CHROMENE DERIVATIVES AND THEIR ANALOGS AS WNT PATHWAY ANTAGONISTS DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) 2016-12-08 US disclosed
US-9371333-B2 Chromene derivatives and their analoga as Wnt pathway antagonists DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) 2016-06-21 US disclosed
US-9371333-B2 Chromene derivatives and their analoga as Wnt pathway antagonists DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) 2016-06-21 US disclosed
US-9371333-B2 Chromene derivatives and their analoga as Wnt pathway antagonists DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) 2016-06-21 US disclosed
US-20130303550-A1 CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS RUPRECHT-KARLS-UNIVERSITAT HEIDELBERG (DE) 2013-11-14 US disclosed
US-20130303550-A1 CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS RUPRECHT-KARLS-UNIVERSITAT HEIDELBERG (DE) 2013-11-14 US disclosed
US-20130303550-A1 CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS RUPRECHT-KARLS-UNIVERSITAT HEIDELBERG (DE) 2013-11-14 US disclosed
US-20130296344-A1 CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS RUPRECHT-KARLS-UNIVERSITAT HEIDELBERG (DE) 2013-11-07 US disclosed
US-20130296344-A1 CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS RUPRECHT-KARLS-UNIVERSITAT HEIDELBERG (DE) 2013-11-07 US disclosed
WO-2012062901-A2 CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS DEUTSCHES KREBSFORSCHUNGSZENTRUM (DKFZ) (DE) 2012-05-18 WO disclosed
WO-2012062905-A2 CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS DEUTSCHES KREBSFORSCHUNGSZENTRUM (DKFZ) (DE) 2012-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303550-A1 CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS WNT3, WNT1, WNT3A MYB 142/4885MEN1 2461/4885KMT2A 3184/4885
US-20160355496-A1 CHROMENE DERIVATIVES AND THEIR ANALOGS AS WNT PATHWAY ANTAGONISTS WNT3, WNT1, WNT3A MYB 152/4885MEN1 2607/4885KMT2A 3925/4885
US-20130296344-A1 CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS WNT3, WNT1, WNT3A MYB 172/4885MEN1 3627/4885KMT2A 3019/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.